Search | Clinical Trials Finder

Conditions: Aortic Aneurysm
Interventions: Exercise MRI; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atopic Dermatitis
Interventions: Fluocinonide; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Amputation, Hyperhidrosis
Interventions: glycopyrronium cloths, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Renal Impairment
Interventions: Tasimelteon; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Renal Insufficiency, Kidney Diseases
Interventions: INCB054707; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Solid Tumours
Interventions: Topotecan; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Scottsdale, Arizona • Lebanon, New Hampshire

Conditions: Normal and Abnormal Cardiovascular Physiology
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 7 Years to 100 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Tibetan Meditation Program, No Meditation; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Renal Impairment
Interventions: Tavapadon; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Jacksonville, Florida • Miami, Florida • Tampa, Florida

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: ASTX727; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Otitis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Renal Impairment
Interventions: PF-04965842; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Amyloidosis, Paraproteinemias, Cardiomyopathies
Interventions: Amyloidosis, Cardiac Amyloidosis; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatic Impairment
Interventions: SAR302503; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Renal Function
Interventions: Ulipristal acetate; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more

Conditions: Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions: BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
Interventions: Adalimumab, Placebo; Drug · Other
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Torrance, California

Conditions: Breast Cancer
Interventions: Improving Cognition with group intervention; Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Renal Insufficiency, Chronic
Interventions: PF-00734200; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Congenital Heart Defects
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatic Impairment
Interventions: Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • San Antonio, Texas

Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: COPD
Interventions: Not listed
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 20 Years to 80 Years
Enrollment: 23 participants
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Murray, Utah

Search by objective public record fields.

Exercise Physiology in Patients With Aortic Aneurysm and Its Correlation With Mechanical Properties of Aortic Tissue

VANOS Cream and Skin Barrier Function

Qbrexza Cloths for Hyperhidrosis of Amputation Sites

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

Technical and Translational Development of Cardiovascular Magnetic Resonance (CMR) Imaging

Meditation and Cognitive Function in Women With Breast Cancer

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Eustachian Tube Testing in a Pressure Chamber -- Validation Study

A Renal Impairment Study for PF-04965842

Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Effects of Altitude on Single-Breath Diffusing Capacity for Carbon Monoxide